<html xmlns="http://www.w3.org/1999/xhtml" xmlns="http://www.w3.org/1999/xhtml">
 <head xmlns="http://www.w3.org/1999/xhtml">
 <title xmlns="http://www.w3.org/1999/xhtml"></title>
 </head>
 <body xmlns="http://www.w3.org/1999/xhtml">
 
 GlycoMimetics, Inc. GLYC today announced new and updated data 
 from the Phase 2 portion of its ongoing Phase 1/2 clinical trial that 
 showed high remission and low mortality rates of its drug candidate 
 GMI-1271, an E-selectin antagonist being developed as a treatment for 
 patients with acute myeloid leukemia (AML). Clinical investigators are 
 presenting the data today from 79 patients in the trial via posters and 
 discussion at the 2017 annual meeting of the <a xmlns="http://www.w3.org/1999/xhtml" href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fam.asco.org%2F&amp;esheet=51569397&amp;newsitemid=20170605005304&amp;lan=en-US&amp;anchor=American+Society+for+Clinical+Oncology&amp;index=1&amp;md5=54d267e7f2af708d2659e097d4402245" rel="nofollow" rel="nofollow">American 
 Society for Clinical Oncology</a> (ASCO) in Chicago. In this trial, 
 patients treated with GMI-1271 together with standard chemotherapy 
 continue to achieve higher than expected remission rates based on 
 historical controls, as well as lower than expected induction-related 
 mortality rates. Treatment also continues to be well tolerated in this 
 patient population.
 
 
 "We are excited to share this promising new data for GMI-1271, which 
 continue to support the potential for this new drug candidate to treat 
 AML, a disease that has often eluded medical interventions thus far," 
 said Rachel King, Chief Executive Officer of GlycoMimetics. "We are 
 increasingly optimistic that GMI-1271 may help address unmet needs in 
 this and other cancers."
 
 
 Among the 54 relapsed/refractory AML patients participating in the trial 
 for whom data is available:
 
 <ul xmlns="http://www.w3.org/1999/xhtml">
 <li xmlns="http://www.w3.org/1999/xhtml" class="bwlistitemmargb">
 The overall response rate (complete remission/complete remission with 
 incomplete marrow recovery, or CR/CRi) was 41 percent, which is higher 
 than historical controls, and the 60-day induction related mortality 
 rate was 7 percent, which is lower than historical controls.
 </li>
 <li xmlns="http://www.w3.org/1999/xhtml" class="bwlistitemmargb">
 Oral mucositis, or inflammation with mouth ulcers that is a sign of 
 adverse effects of chemotherapy, was seen at low rates and severity 
 with only one Grade 3/4 event observed.
 </li>
 <li xmlns="http://www.w3.org/1999/xhtml" class="bwlistitemmargb">
 The median overall survival time for Phase 1 trial patients was 7.6 
 months.
 </li>
 <li xmlns="http://www.w3.org/1999/xhtml" class="bwlistitemmargb">
 Remissions were durable enough to allow 9 patients to receive stem 
 cell transplants.
 </li>
 <li xmlns="http://www.w3.org/1999/xhtml" class="bwlistitemmargb">
 For patients in the Phase 1 portion of the trial who responded with a 
 remission, more than half survived for at least a year after treatment.
 </li>
 </ul>
 
 Among the 25 newly diagnosed elderly patients (age 60 and older) 
 participating in the trial for whom data is available:
 
 <ul xmlns="http://www.w3.org/1999/xhtml">
 <li xmlns="http://www.w3.org/1999/xhtml" class="bwlistitemmargb">
 The overall response (CR/CRi) rate was 68 percent, with 73 percent in 
 patients with de novo AML and 64 percent in patients with secondary 
 AML.
 </li>
 <li xmlns="http://www.w3.org/1999/xhtml" class="bwlistitemmargb">
 The 60-day mortality rate was 8 percent.
 </li>
 <li xmlns="http://www.w3.org/1999/xhtml" class="bwlistitemmargb">
 There were no cases of grade 3 or 4 mucositis.
 </li>
 <li xmlns="http://www.w3.org/1999/xhtml" class="bwlistitemmargb">
 For the 9 evaluable patients achieving CR/CRi, disease-free survival 
 was 100% at 6 months after treatment.
 </li>
 </ul>
 
 "These results are very encouraging, indicating that the E-selectin 
 antagonist may enhance our ability to improve the 
 complete remission rate and potentially to improve the tolerability of 
 intensive chemotherapy for patients with acute myeloid leukemia," said 
 Daniel J. DeAngelo, MD, PhD, the trial's Lead Investigator, who serves 
 as Dana-Farber Cancer Institute Director of Clinical and Translational 
 Research, Adult Leukemia, and Institute Physician, and Associate 
 Professor of Medicine at Harvard Medical School. "We look forward to 
 continuing our clinical testing of GMI-1271 and further examining its 
 potential for improving outcomes for patients with AML."
 
 
 The ASCO Annual Meeting is taking place from June 2-5, 2017 at McCormick 
 Place in Chicago. More detail and the meeting abstracts are available at <a xmlns="http://www.w3.org/1999/xhtml" href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fam.asco.org%2F&amp;esheet=51569397&amp;newsitemid=20170605005304&amp;lan=en-US&amp;anchor=ASCO%27s+website&amp;index=2&amp;md5=d3a644272ef553d37b9bae969f4f5ce3" rel="nofollow" rel="nofollow">ASCO's 
 website</a>.
 
 
 Data from the Phase 1/2 trial were submitted to the U.S. Food and Drug 
 Administration (FDA). In May 2017, the FDA granted GMI-1271 Breakthrough 
 Therapy designation for treatment of adult patients with 
 relapsed/refractory AML. In addition, GMI-1271 has been granted Orphan 
 Drug designation and Fast Track status by the FDA and Orphan Drug 
 designation by the European Commission.
 
 
 About GlycoMimetics, Inc.
 
 
 GlycoMimetics is a clinical-stage biotechnology company focused on 
 cancer and sickle cell disease. GlycoMimetics' most advanced drug 
 candidate, rivipansel, a pan-selectin antagonist, is being developed for 
 the treatment of vaso-occlusive crisis in sickle cell disease and is 
 being evaluated in a Phase 3 clinical trial being conducted by its 
 strategic collaborator, Pfizer. GlycoMimetics&#39; wholly-owned drug 
 candidate, GMI-1271, an E-selectin antagonist, is being evaluated in an 
 ongoing Phase 1/2 clinical trial as a potential treatment for AML and in 
 a Phase 1 clinical trial in multiple myeloma. The U.S. FDA recently 
 granted GMI-1271 Breakthrough Therapy designation for treatment of adult 
 AML patients with relapsed/refractory disease. GlycoMimetics has also 
 recently initiated a clinical trial with a third drug candidate, 
 GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is 
 located in Rockville, MD in the BioHealth Capital Region. Learn more at <a xmlns="http://www.w3.org/1999/xhtml" href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.glycomimetics.com&amp;esheet=51569397&amp;newsitemid=20170605005304&amp;lan=en-US&amp;anchor=www.glycomimetics.com&amp;index=3&amp;md5=e4e700efdd166a2bb171d615fdb6e549" rel="nofollow" rel="nofollow">www.glycomimetics.com</a>.
 
 
 Forward-Looking Statements
 
 
 This press release contains forward-looking statements regarding 
 GlycoMimetics&#39; planned activities with respect to the clinical 
 development of its drug candidate GMI-1271. Actual results may differ 
 materially from those indicated by such forward-looking statements as a 
 result of various important factors, including the availability and 
 timing of data from ongoing clinical trials, the uncertainties inherent 
 in the completion of ongoing clinical trials and the initiation of 
 future clinical trials, whether interim results from a clinical trial 
 will be predictive of the final results of the trial or results of early 
 clinical trials will be indicative of the results of future trials, 
 expectations for regulatory approvals, availability of funding 
 sufficient for GlycoMimetics&#39; foreseeable and unforeseeable operating 
 expenses and capital expenditure requirements, other matters that could 
 affect the availability or commercial potential of GlycoMimetics&#39; drug 
 candidates and other factors discussed in the &#34;Risk Factors&#34; section of 
 GlycoMimetics&#39; Annual Report on Form 10-K that was filed with the U.S. 
 Securities and Exchange Commission on March 1, 2017, and other 
 filings GlycoMimetics makes with the Securities and Exchange 
 Commission from time to time. In addition, the forward-looking 
 statements included in this press release represent GlycoMimetics&#39; views 
 as of the date hereof. GlycoMimetics anticipates that subsequent events 
 and developments may cause its views to change. However, 
 while GlycoMimetics may elect to update these forward-looking statements 
 at some point in the future, GlycoMimetics specifically disclaims any 
 obligation to do so, except as may be required by law. These 
 forward-looking statements should not be relied upon as representing 
 GlycoMimetics&#39; views as of any date subsequent to the date hereof.
 
 
 
 <img xmlns="http://www.w3.org/1999/xhtml" alt="" src="http://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20170605005304r1&amp;sid=benz2&amp;distro=nx&amp;lang=en"></img>View source version on businesswire.com: <a xmlns="http://www.w3.org/1999/xhtml" href="http://www.businesswire.com/news/home/20170605005304/en/" rel="nofollow" rel="nofollow">http://www.businesswire.com/news/home/20170605005304/en/</a></body></html>

Press Releases

GlycoMimetics Presents Updated Data from Ongoing Phase 1/2 Clinical Trial of GMI-1271 in Patients with Acute Myeloid Leukemia at ASCO 2017 Annual Meeting - GlycoMimetics (NASDAQ:GLYC)

GlycoMimetics

GLYC

GlycoMimetics Presents Updated Data from Ongoing Phase 1/2 Clinical Trial of GMI-1271 in Patients with Acute Myeloid Leukemia at ASCO 2017 Annual Meeting

RIVN


Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Rivian Automotive, Inc. (NADSAQ: RIVN) common stock between March 1, 2023

Rivian Automotive, Inc. (RIVN) Investor Notice: Robbins LLP Reminds Stockholders of the Rivian Automotive, Inc. Class Action Lawsuit


Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Global Cord Blood Corporation (NYSE:CO) securities between June 4, 2019

Global Cord Blood Corporation (CO) Investor Notice: Robbins LLP Reminds Stockholders of the Global Cord Blood Corporation Class Action


One of the main roles of the spleen is to help the body&#39;s immune system fight infections. The spleen does this through producing and regulating antibodies – antibody production is negatively affected in various

Vagus nerve activation of the spleen shows promise to treat infections, Feinstein Institutes research

LFGP


Ledyard Financial Group, Inc. ((the &#34;Company&#34;, OTCQX:LFGP), the holding company for Ledyard National Bank (the &#34;Bank&#34;), today announced financial results for Q1 2024. The balance sheet growth in the quarter is evidence

Ledyard Financial Group Reports Q1 2024 Earnings and Declares Quarterly Dividend


Fonon Corporation, a multi-market holding company, R&amp;D center, equipment designer and manufacturer of advanced laser material processing systems for subtractive and additive manufacturing, highlights applications

Fonon Highlights Its Zero Width Laser Cutting Solution for Flat Panel Display Manufacturing


AM Best has maintained the under review with developing implications status for the Financial Strength Rating of A- (Excellent) and the Long-Term Issuer Credit Ratings of &#34;a-&#34; (Excellent) of Accredited Specialty